Foravirumab/Rafivirumab
N/A
Report date: 2022/07/04 19:38:02
Base Information
Drug NameForavirumab/Rafivirumab
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsYes Foravirumab
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCrucell Holland BvJohnson & Johnson
China Registration ClassN/A
Develop Information
Other Information
ATC CodeN/A
Related LinksN/A